China: Sinovac Biotech to delist from Nasdaq, enters private deal for $401.8m

China: Sinovac Biotech to delist from Nasdaq, enters private deal for $401.8m

Visual from company website.

In a taking-private transaction valued at $401.8 million deal, Chinese biopharmaceutical products company Sinovac Biotech Ltd is delisting from the US stock market Nasdaq.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter